Jefferies Financial Group Inc. Invests $1.52 Million in Omnicell, Inc. $OMCL

Jefferies Financial Group Inc. bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 36,712 shares of the company’s stock, valued at approximately $1,524,000. Jefferies Financial Group Inc. owned approximately 0.08% of Omnicell as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Dana Investment Advisors Inc. purchased a new stake in shares of Omnicell during the fourth quarter valued at approximately $3,445,000. Bank of America Corp DE boosted its stake in shares of Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the period. Jackson Creek Investment Advisors LLC purchased a new position in shares of Omnicell in the fourth quarter valued at $2,022,000. Dimensional Fund Advisors LP grew its holdings in Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares in the last quarter. Finally, Peregrine Capital Management LLC grew its holdings in Omnicell by 27.2% during the 1st quarter. Peregrine Capital Management LLC now owns 134,894 shares of the company’s stock valued at $4,503,000 after purchasing an additional 28,835 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OMCL. Wells Fargo & Company decreased their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Piper Sandler restated an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Finally, Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $33.08 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 39.38, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98. Omnicell, Inc. has a twelve month low of $29.06 and a twelve month high of $55.00. The business has a 50 day simple moving average of $39.80 and a 200-day simple moving average of $39.33.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities research analysts expect that Omnicell, Inc. will post 1.41 earnings per share for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.